8.5 Repackaging, Unit-Dose Beyond-Use Dating & FDA Drug Recall Classifications

Repackaging, Patient Med-Paks, BUDs, and Recalls

Repackaging moves a drug from its marketed container into another package. It can improve workflow and adherence, but the new container may change protection from moisture, light, air, or contamination. The pharmacy must preserve identity, lot/expiration traceability, labeling, and recall capability.

Prepackaged pharmacy stock

Under Mississippi Article XI, drugs ordinarily remain in the manufacturer’s or repackager’s original labeled container. Precounted stock and automated-counting containers used for dispensing must remain identifiable by manufacturer lot number and expiration date. A pharmacy-assigned date may never extend the manufacturer expiration or exceed stability supported for the new package.

The record identifies drug, strength, dosage form, manufacturer, source lot, source expiration, quantity, package type, packaging date, assigned expiration/BUD, personnel packaging, and pharmacist check. Different lots are not combined without preserving complete traceability.

Customized patient med-paks

A pharmacist may provide a customized patient medication package with consent of the patient, caregiver, or prescriber. The package bears all traditional prescription-label information plus a unique med-pak identification number, date of preparation, and a BUD not exceeding 90 days from preparation. Separable portions retain the information needed for safe identification and use.

The pharmacy assesses whether each product is suitable for the shared package. Moisture-sensitive, light-sensitive, hazardous, effervescent, refrigerated, or interaction-prone products may require exclusion. A 90-day maximum is not automatic stability proof; use a shorter date when product or packaging demands it.

LTCF unit-dose and unit-of-issue packaging

Article XXX establishes packaging and dating conditions for nonsterile medication supplied to long-term-care facilities. The package preserves identity and integrity and uses suitable USP <671> Class A or B containers for oral solids or tight containers for liquids, with light resistance when required.

An assigned expiration may exceed 90 days from repackaging only when those packaging conditions and manufacturer recommendations support it. Even then, it may not exceed 12 months or the manufacturer’s original expiration, and products with known stability problems require a shorter period. Do not apply the 12-month LTCF unit-dose ceiling automatically to a community vial or med-pak.

In-house unit-dose packaging identifies the drug, strength, lot/control number, expiration, and other required information and supports recall. Pharmacy supervision and final checking establish responsibility.

Recalls

FDA recall classes describe health risk: Class I involves a reasonable probability of serious adverse health consequences or death; Class II involves temporary or medically reversible adverse effects or a remote probability of serious effects; Class III is unlikely to cause adverse health consequences. The classification guides urgency but does not authorize dispensing recalled stock.

On notice, verify manufacturer, product, NDC, lot, expiration, and depth. Immediately quarantine affected on-hand stock physically and electronically. Stop dispensing, identify transfers and patient dispensings within recall scope, notify patients, practitioners, facilities, and regulators as required, reconcile quantities, return or destroy through the instructed pathway, and document completion. A market withdrawal and safety alert may require different action, so read the notice.

Exam method

Identify the packaging pathway before choosing a date: med-pak ≤90 days, qualifying LTCF package may exceed 90 but ≤12 months and manufacturer expiration, other prepackaging based on supported packaging stability. For recall, use lot-level traceability and quarantine first.

Packaging comparison example

A community adherence med-pak prepared June 1 cannot use a date beyond August 30 merely because each source bottle expires next year; the med-pak’s 90-day ceiling applies and stability may require less. A qualifying LTCF unit-dose package can exceed 90 days only with the specified protective container, light protection where needed, manufacturer support, and a final date no later than 12 months or source expiration.

If a recall covers lot ABC, records should identify whether ABC entered prepackaged vials, med-paks, unit doses, automated stock, or finished compounds. Quarantine remaining units, identify affected patients and facilities within recall depth, document contacts and nonresponses, reconcile returned and destroyed quantities, and preserve the manufacturer notice and completion evidence. Without lot-level packaging records, patient protection becomes guesswork.

Temperature excursions during storage can shorten or invalidate an assigned date even when the printed BUD has not arrived. Segregate affected packages, obtain stability guidance, identify recipients if product was released, and document the decision.

A repackaged label must remain legible and attached throughout storage and use. If a separated med-pak cell no longer identifies the patient, drug, strength, and administration time as required, the convenience design has defeated safe dispensing and must be corrected before release.